Project Grant R01CA318242
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $713K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
- The National Institutes of Health National Cancer Institute awarded Icahn School of Medicine at Mount Sinai $827,111 on July 21, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the role of the proline hydroxylase P4HA2 in metastatic tumor dormancy and the dormancy-to-reactivation transition. The project examines how dormant disseminated tumor cells regulate collagen extracellular matrix formation through control of proline hydroxylation, hypothesizing that P4HA2...
- The National Cancer Institute awarded Icahn School of Medicine at Mount Sinai $642,242 on May 15, 2026, under the Cancer Biology Research program (CFDA 93.396, R01 CA303558) to investigate the function and therapeutic implications of neuregulin 3 (NRG3) in breast cancer brain metastasis. The project will elucidate the role of neuron-derived NRG3 in promoting brain metastasis in luminal breast cancer models that exhibit low brain metastasis association at diagnosis. The research will...
- The National Cancer Institute awarded Icahn School of Medicine at Mount Sinai $683,256 on May 22, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop and validate a human-mouse platform for patient stratification and therapeutic target discovery in glioblastoma. The recipient will integrate single-cell RNA-sequencing data from 199 glioblastoma patients with spatial transcriptomics technologies to dissect tumor microenvironment cell composition, spatial tissue organization,...
- The National Cancer Institute awarded Albert Einstein College of Medicine $2.038 million on August 26, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate mechanisms of early breast cancer local and distant relapse. The award supports a Project Grant (P01CA295557) with a period of performance through July 31, 2031, and place of performance in Bronx, New York. The research examines how disseminated cancer cells remain dormant in new tissue microenvironments and...
- The National Cancer Institute awarded The Trustees of Columbia University in the City of New York $105,232 on December 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research dissecting mechanisms, novel therapies, and human correlates of metastatic reactivation from dormancy. The research employs spatial transcriptomics and whole-genome sequencing to characterize spatiotemporal dynamics of cancer cells and tumor microenvironment changes during...
- The National Cancer Institute awarded Albert Einstein College of Medicine $168,000 on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate dormancy and recurrence mechanisms in pancreatic ductal adenocarcinoma. The research examines how disseminated tumor cells in pancreatic cancer patients enter a dormant state, allowing minimal residual disease to persist after surgery and chemotherapy despite high initial response rates. The project focuses on two...
- The National Cancer Institute, a division of the Department of Health and Human Services National Institutes of Health, awarded Health Research, Inc. (Roswell Park Division) $446,112 on July 3, 2026, under the Cancer Biology Research program (CFDA 93.396) to identify age-regulating breast cancer dormancy genes using C. elegans dauer models. The project investigates how chronological aging of dormant cancer cells drives metastatic relapse and reawakening after initial treatment. The recipient...
- The National Institutes of Health National Cancer Institute awarded Icahn School of Medicine at Mount Sinai $628,394 on May 8, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop and validate a patient-derived organoid with tumor microenvironment (PDOT) co-culture system for modeling therapeutic responses in intrahepatic cholangiocarcinoma. The recipient will establish a precision preclinical platform that simultaneously reconstitutes intrahepatic cholangiocarcinoma...
- The National Institutes of Health National Cancer Institute awarded Albert Einstein College of Medicine $431,970 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to refine and validate an MRI-based imaging technique for detecting tumor microenvironment of metastasis (TMEM) doorways in breast cancer. The award funds development of TMEM doorway activity-MRI (TDAM), a dynamic contrast-enhanced MRI method designed to measure vascular opening events...
- The National Cancer Institute awarded Cold Spring Harbor Laboratory $675,617 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate intercellular metabolic and signaling mechanisms of brain cancer-glia communication driving glioblastoma progression. The project examines how glioblastoma cells reprogram brain microglia—the brain's resident immune cells—to create an immunosuppressive tumor microenvironment that promotes tumor growth. The research focuses on an...